EFSD European Foundation for the Study of Diabetes

Report - 2011
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td><strong>Grant Programmes 2011:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>EFSD</strong></td>
<td></td>
</tr>
<tr>
<td>Clinical Research Grants in the Field of Diabetes</td>
<td>6</td>
</tr>
<tr>
<td><strong>EFSD</strong></td>
<td></td>
</tr>
<tr>
<td>Research Programme in Diabetes and Cancer</td>
<td>7</td>
</tr>
<tr>
<td><strong>EFSD</strong></td>
<td></td>
</tr>
<tr>
<td>New Horizons Collaborative Research Initiative</td>
<td>8</td>
</tr>
<tr>
<td><strong>EFSD/Amylin</strong></td>
<td></td>
</tr>
<tr>
<td>Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes</td>
<td>9</td>
</tr>
<tr>
<td><strong>EFSD</strong></td>
<td></td>
</tr>
<tr>
<td>European Diabetes Research Programme in Patient Education supported by an educational research grant from AstraZeneca/BMS</td>
<td>10</td>
</tr>
<tr>
<td><strong>EFSD/Chinese Diabetes Society/Lilly</strong></td>
<td></td>
</tr>
<tr>
<td>Collaborative Diabetes Research Programme</td>
<td>11</td>
</tr>
<tr>
<td><strong>EFSD/JDRF/Novo Nordisk</strong></td>
<td></td>
</tr>
<tr>
<td>European Programme in Type 1 Diabetes Research</td>
<td>12</td>
</tr>
<tr>
<td><strong>EFSD/JDRF</strong></td>
<td></td>
</tr>
<tr>
<td>Young Investigator Awards in Innovative Therapy for Type 1 Diabetes supported by an unrestricted grant from Roche</td>
<td>13</td>
</tr>
<tr>
<td><strong>EFSD/Janssen</strong></td>
<td></td>
</tr>
<tr>
<td>Programme for the Study of the Role of the Kidney in Diabetes</td>
<td>14</td>
</tr>
<tr>
<td><strong>EFSD/Lilly</strong></td>
<td></td>
</tr>
<tr>
<td>European Diabetes Research Programme</td>
<td>15</td>
</tr>
<tr>
<td><strong>EFSD/Lilly</strong></td>
<td></td>
</tr>
<tr>
<td>Mental Health and Diabetes Programme</td>
<td>16</td>
</tr>
<tr>
<td><strong>EFSD/Merck Sharp &amp; Dohme (MSD)</strong></td>
<td></td>
</tr>
<tr>
<td>European Basic Research Programme on Beta Cell Function and Survival</td>
<td>17</td>
</tr>
<tr>
<td><strong>EFSD/Novo Nordisk</strong></td>
<td></td>
</tr>
<tr>
<td>Partnership for Diabetes Research in Europe</td>
<td>18</td>
</tr>
<tr>
<td><strong>EFSD/Sanofi</strong></td>
<td></td>
</tr>
<tr>
<td>European Research Programme in Micro- and Macrovascular Complications of Diabetes</td>
<td>19</td>
</tr>
</tbody>
</table>
**Fellowships 2011:**

**EFSD Albert Renold**  
Travel Fellowships supported by *Merck Sharp & Dohme (MSD)*  

**EFSD/Chinese Diabetes Society/Lilly**  
Research Fellowships

**EFSD/Lilly**  
Research Fellowships

**EFSD/MSD**  
Fellowships for Research on the Endocrine Pancreas

**New Programmes for 2012:**

**EFSD/Boehringer Ingelheim**  
European Diabetes Research Programmes

**EFSD/Janssen**  
Rising Star Fellowships

**EFSD/Japanese Diabetes Society**  
Reciprocal Travel Fellowships

**EFSD/JDRF/Novo Nordisk**  
Research Fellowships

**EFSD/Sanofi**  
Clinical Research Fellowships

*Note: the above relates solely to programmes which have been officially agreed at the time of writing this Report.*
In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

**EFSD and its partners bring over Euro 82 Million to European diabetes research**

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over Euro 82 Million to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in Diabetologia (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.
GRANT

PROGRAMMES

2011
Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. The proposed investigation must be carried out in humans; although in vitro and ex vivo studies are acceptable, the in vivo component must clearly be the more relevant part of the project.

Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme has committed a total of Euro 6.2 million towards clinical research in diabetes.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Constantinos Christodoulides: University of Oxford - UK
Luigi Gnudi: King's College London - UK
Neil Reeves: Manchester Metropolitan University - UK
Margaret Robertson: Surrey University - Guildford, UK
Research Programme in Diabetes and Cancer

Plan

The EFSD Research Programme in Diabetes and Cancer was established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest, and applications for projects carried out in collaboration between diabetes and cancer research institutions are especially welcome.

Funding Commitment and Instruments

Euro 3.75 million has been made available from 2010 - 2013 in the framework of the Programme.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Pietro Formisano: Università di Napoli "Federico II" - Italy
Derek LeRoith: Rambam Health Care Campus – Haifa, Israel
Jaakko Tuomilehto: University of Helsinki - Finland
Sarah Wild: Edinburgh University - UK
New Horizons Collaborative Research Initiative

Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed. The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative.

This Programme therefore aims to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Funding Commitment and Instruments

Up to Euro 2.4 million was made available for the period 2009 - 2011 to fund basic and clinical research grants.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gábor Firneisz: Semmelweis University - Budapest, Hungary collaborating with Alexandra Kautzky-Willer: Medical University of Vienna - Austria
Igor Lacik: Slovak Academy of Sciences - Bratislava, Slovakia collaborating with Terje Espevik: University of Science & Technology - Trondheim, Norway
Jan Lebl: Charles University - Prague, Czech Republic collaborating with Torben Hansen: University of Copenhagen - Denmark
Paul Langerhans Grants on Interaction Peripheral Tissues, the Gut and the Central Nervous System

Background

Amylin Pharmaceuticals, Inc. was founded in 1987 on the discovery of a hormone, amylin, that is produced with insulin by beta cells. Built on a strong foundation of research, Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialisation of novel therapies for metabolic diseases.

Plan

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis, which evolved in 2011 to fund studies addressing the notion that the gastrointestinal tract plays an important role in the pathogenesis of diabetes. These grant awards honour the memory of Paul Langerhans, who discovered the islet cells of the pancreas.

Funding Commitments and Instruments

Since its creation in 2005, the total funding commitment of the Partnership has reached Euro 1.5 million.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Rinke Stienstra: Radboud University Nijmegen - The Netherlands
Marie Björnholm: Karolinska Institute – Stockholm, Sweden
Angela Valverde: Spanish National Research Council (CSIC) – Madrid, Spain
European Diabetes Research Programme in Patient Education

supported by an educational research grant from AstraZeneca/BMS

**Background**

The AstraZeneca/Bristol-Myers Squibb diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

**Plan**

This Programme supports research into the clinical and medical evaluation of patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management and the potential impact of educational and disease management programmes, focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease.

**Funding Commitment and Instruments**

A total of **Euro 1.2 million** for research funding will be distributed over three years from 2011 – 2013.

**Awards in 2011**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Kathleen Abu-Saad: Sheba Medical Centre - Ramat Gan, Israel
Ingrid Mühlhauser: University of Hamburg - Germany
Programme for Collaborative Diabetes Research between China and Europe

Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly has for more than 85 years been a worldwide leader in diabetes care. Based in Indianapolis, USA Lilly introduced the world's first commercial insulin in 1923 and remains at the forefront of pharmaceutical and delivery-device innovation to manage diabetes.

Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Funding Commitment and Instruments

Since its inception in 2008, a total funding commitment of **Euro 2.6 million** has been made to this Programme for research to be carried out in China in collaboration with a European research institution.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Ronald Ma: Hong Kong Institute of Diabetes & Obesity - China **collaborating with**
Mark Hanson: University of Southampton - UK
Youqing Wang: Beijing University of Chemical Technology - China **collaborating with**
Claudio Cobelli: University of Padova - Italy
Dijing Zhi: Fudan University - Shanghai, China **collaborating with**
Carani Sanjeevi: Karolinska Institute - Stockholm, Sweden
Lei Zhou: Huazhong Agricultural University - Wuhan City, China **collaborating with**
Jürgen Eckel: German Diabetes Center - Düsseldorf, Germany
European Programme in Type 1 Diabetes Research

Background
The mission of JDRF is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan
The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications.

Funding Commitment and Instruments
The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has to date made a total combined commitment of €12.3 million.

Awards in 2011
Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Mirko Pham: Heidelberg University Hospital - Germany
Eliane Piaggio: Hospital Pitié-Salpêtrière - Paris, France
Flemming Pociot: Glostrup Research Institute - Denmark
Peter van Endert: Paris Decartes University - France
Young Investigator Awards in Innovative Therapy for Type 1 Diabetes
supported by an unrestricted grant from Roche

Background

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.

Plan

These Young Investigator Awards were established to promote increased European research in innovative therapy for type 1 diabetes, and to support young scientists within Europe during their transition towards independence.

Funding Commitment and Instruments

A total commitment of Euro 360,000 has been allocated to this Programme.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Eduard Ayuso: Autonomous University Barcelona - Spain
Luc Baeyens: Free University Brussels - Belgium
Paola Bonfanti: Free University Brussels - Belgium
Geert Martens: Free University Brussels - Belgium
Programme for the Study of the Role of the Kidney in Diabetes

Background

Janssen represents the pharmaceutical companies of Johnson and Johnson, one of the leading healthcare companies in the world. Janssen develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world, with metabolic diseases as a key area of scientific interest.

Plan

This Programme is intended to stimulate and accelerate European research aimed at understanding the role of the kidney in diabetes, with special emphasis on the role of the renal glucose threshold (RGT) as an underlying pathophysiologic mechanism in type 2 diabetes. Both basic and clinical research in this scientific area will be supported.

Funding Commitment and Instruments

A total of Euro 500,000 for research funding has been made available from 2001 – 2013 to support the award of grants.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Paul Squires: University of Warwick - UK
European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003, the Fund has now reached a total commitment of Euro 12.640 million to fund its various activities, including research grant and fellowship programmes.

Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has committed Euro 7.4 million towards the EFSD/Lilly Diabetes Research Grant Programme.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Peter Arner: Karolinska Institute - Stockholm, Sweden
Mireille Cormont: University of Nice - France
Mirela Delibegovic: University of Aberdeen - UK
Helene Duez: University of Lille - France
Anthony Gavalas: Academy of Athens - Greece
Eran Hornstein: Weizmann Institute of Science - Rehovot, Israel
Joel Le Maoult: St Louis Hospital - Paris, France
Carles Lerin: IDIBAPS - Barcelona, Spain
Stefan Trapp: Imperial College London - UK
Mental Health and Diabetes Programme

**Background**

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

**Plan**

This Programme is aimed at clinical investigations into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and Alzheimer's. Special emphasis should be given to improving the co-operation between psychiatric and diabetes care.

**Funding Commitment and Instruments**

In 2011, a further Euro 750,000 was allocated for a three-year programme from 2011 – 2013, bringing the total commitment to Euro 1 million.

**Awards in 2011**

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Geert Biessels: University Medical Center Utrecht - The Netherlands
Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

This Programme aims to stimulate and accelerate European research focusing on the following: incretin physiology, DPP-4 inhibition, gut physiology as it relates to metabolic control, and islet cell function and survival.

Funding Commitment and Instruments

This partnership Grant Programme was established in 2005 and renewed in 2007 for a total commitment of Euro 6.1 million.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gabriela da Silva Xavier: Imperial College London - UK
Thierry Ferreira: Poitiers University - France
Dominique Gauguier: Cordeliers Research Centre - Paris, France
Guy Rutter: Imperial College London - UK
Ram Weiss: The Hebrew University - Jerusalem, Israel
Partnership for Diabetes Research in Europe

Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

Plan

This new Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

Funding Commitments and Instruments

This Programme continues the longstanding EFSD/Novo Nordisk Partnership, with a combined total commitment amounting to Euro 8.9 million.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Henning Beck-Nielsen: Odense University Hospital - Denmark
Miriam Cnop: Free University of Brussels - Belgium
Michael Elkin: Hadassah-Hebrew University - Jerusalem, Israel
Luis Graca: University of Lisbon - Portugal
Anders Rosengren: Lund University - Malmö, Sweden
Hubert Vidal: South Lyon Medical Facility - France
Suvi Virtanen: National Institute for Health and Welfare - Helsinki, Finland
European Research Programme in Micro- and Macrovascular Complications of Diabetes

Background

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes, aiming to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes, strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions.

Funding Commitment and Instruments

Since its creation in 2006, the EFSD/Sanofi Partnership has made available a total of Euro 3.6 million to fund basic research projects.

Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Tim Curtis: Queen's University of Belfast - UK
Guiseppe Pugliese: La Sapienza University - Rome, Italy
Casper Schalkwijk: University Hospital Maastricht - The Netherlands
Sidney Shaw: University of Bern - Switzerland
Marja-Riitta Taskinen: Helsinki University Central Hospital - Finland
Thomas Wieland: University of Heidelberg - Germany
FELLOWSHIP

PROGRAMMES

2011
Albert Renold Fellowships
Supported by an unrestricted educational grant from Merck Sharp & Dohme (MSD)

Albert Renold Fellowships, each of up to Euro 7,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months. Albert Renold Fellowships are available throughout the year, and a decision is usually made within three weeks of applying. Since its inception a total of Euro 1 million has been allocated to recipients of this Fellowship Programme.

In 2011 the following Fellowships were awarded:

Louisa Cheung: visiting Rangueil Institute - Toulouse, France
Kyriakoula Marinou: visiting Oxford University - UK
Zoltan Kender: visiting University of Heidelberg - Germany
Michael Willenberg: visiting University of Maribor - Slovenia
Konstantinos Michalakis: visiting University of London - UK
Ellen Dirkx: visiting University of Texas - Dallas, USA
Julia Winkler: visiting Zurich Institute of Technology - Switzerland
Melita Vidakovic: visiting Miguel Hernandez University - Elche, Spain
Teatske Altenburg: visiting Baker IDI Heart & Diabetes Institute - Melbourne, Australia
Elisa Corsiero: visiting Max-Planck Institute - Berlin, Germany
Payal Nandkumar Shah: visiting Uppsala University - Sweden
Merewyn Loder: visiting Kobe University - Japan
Senthil Vasan: visiting University of Oxford - UK
Silvie Timmers: visiting Federal Institute of Technology - Lausanne, Switzerland
Alex Rafacho: visiting University of Geneva - Switzerland
Nujen Colak Bozkurt: visiting University of Miami - USA
Romyna La Rosa Vasquez: visiting San Carlos University Hospital - Madrid, Spain
Daniele Lisboa Ribeiro: visiting Lund University - Sweden
Berengere Valtat: visiting Lund University - Sweden
Kathrin Schmeißer: visiting University College London - UK
Tijana Mitic: visiting Monzino Cardiology Centre - Rome, Italy
Christina Mallol: visiting Joslin Diabetes Center - Boston, USA
Diana Rosa Milla Flores: visiting San Carlos University Hospital - Madrid, Spain
Sandra Rebuffat: visiting Faculty of Pharmacology - Montpellier, France
Margarita Jimenez Palomares: visiting University of Michigan - Ann Arbor, USA
Tess Lu: visiting Research Center for Molecular Medicine - Vienna, Austria
Peter Plomgaard: visiting University of Geneva - Switzerland
Yvo Kusters: visiting University of Virginia – Charlottesville, USA
Menang Joshua Ngwan: visiting Geneva University Hospital - Switzerland
Jana Breitfeld: visiting University of Barcelona - Spain
Alice Zoso: visiting University of Geneva - Switzerland
Tina Ines Ullrich: visiting University of Alberta – Edmonton, Canada
Valentina Di Caro: visiting University of Pittsburgh - USA
The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from young investigators from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 50,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

The Fellowship Programme was renewed for a three-year term in 2011, bringing the total funding commitment to date to Euro 600,000.

No awards were made through this Programme in 2011.
Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education. To date, Euro 1.75 million has been allocated to this Programme.

Each Fellowship Award is up to Euro 50,000. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under “EFSD/Lilly Diabetes Research Programme”.

In 2011 the following Fellowships were awarded:

Romain Barrés: University of Copenhagen - Denmark
Federica Barutta: University of Turin - Italy
Vladimer Darsalia: Karolinska Institute - Stockholm, Sweden
Lorenzo Pasquali: IDIBAPS - Barcelona, Spain
Matthew Simmonds: University of Oxford - UK
Tom Van Belle: Ghent University - Belgium
Nicolas Venteclaf: Pierre and Marie Curie University - Paris, France
Fellowships for Research on the Endocrine Pancreas

The objective of the EFSD/MSD Research Fellowships was to encourage innovative research focusing on the endocrine pancreas and to support talented young investigators engaged in diabetes research.

Postdoctoral Fellowships in the amount of Euro 50,000 were awarded to individuals already holding a PhD, MD or equivalent degree under the age of 38 years on 1 January 2011.

EFSD/MSD Fellows are expected to change their place and ideally country of work during the funding period in order to pursue their research project in a new academic environment. However, either the current home or proposed host institution must be based in Europe or an associated country.

These Fellowships form part of the EFSD/MSD initiative, further details of which may be found under the EFSD/Merck Sharp & Dohme Programme.

In 2011 the following Fellowships were awarded:

Shanna Tam: St Vincent's Institute, Fitzroy - Australia
Jakob Wikstrom: Hebrew University, Jerusalem - Israel
NEW PROGRAMMES

2012
European Diabetes Research Programmes

Background

Boehringer Ingelheim is a global group of companies that seek to improve the health and well being of people and animals through being a part of an independent, innovative, research and development driven company.

Plan

In order to encourage new projects aimed at advancing current knowledge in this domain, EFSD and Boehringer Ingelheim have established a new partnership called the EFSD/Boehringer Ingelheim European Diabetes Research Programmes. These Programmes consist of two elements, each with a different focus:

Basic Research Programme: Regulation of Secretion and Function of Non-Insulin Peptides from the Endocrine Pancreas
Applications dealing with research into the role, function and mechanism of non-beta cells are especially, but not exclusively, welcome.

Clinical Research Programme: Mechanisms Relating Renal Dysfunction to Cardiovascular Disease in Type 2 Diabetes
Projects investigating novel biomarkers or the translation of experimental hypotheses and clinical results are especially, but not exclusively, welcome.

Funding Commitment and Instruments

A total of Euro 2.5 million for research funding will be distributed over three years in 2012 – 2014.

The deadline date for this Programme is 1 April 2012.
Rising Star Fellowships

The Rising Star Symposium aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at this year’s EASD Annual Meeting. Four candidates will be selected, two in basic research and two in clinical research. The chosen candidates will be invited by EASD to present a lecture (25 minute lecture + 5 minute discussion) and will receive a commemorative diploma. Travel expenses, hotel and registration costs for the recipients will be covered.

Furthermore the award includes a research fellowship in the amount of Euro 30,000 payable to the applicant’s institution. The objective of the research fellowship is to encourage innovative research in the field of diabetes. Applicants should have demonstrated their ability in the field of diabetes research.

Candidates for the Rising Star Symposium must be paid-up members of EASD and have a PhD, MD or equivalent degree. The candidates must be under the age of 38 on 1 January in the year of the award. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

The deadline date for this programme is 1 February 2012.
Reciprocal Travel Research Fellowships

The objective of the EFSD/JDS Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for Fellowships to carry out a scientific project will be accepted from applicants working in Japan to travel to Europe or its associated countries and also from those working in Europe or its associated countries to travel to Japan. The host institution must be a recognised academic research institution and applicants should have demonstrated their ability in the field of diabetes research.

Up to four Fellowships will be awarded, each in the sum of Euro 50,000. Awards will be paid into the account of the recipients’ home institution. The scientific project will be three to twelve months in length with some extra time allowed to complete a language course. The budget may include items such as: salaries, travel, sustenance and consumables. The recipients must start the fellowship within 6 months of notification.

Applications may be made by any scientist or clinician who has been working in a postdoctoral position no longer than five years. Each applicant will need to provide a Letter of Support from both the home and the host institution.

The deadline date for this programme is 15 March 2012.
Research Fellowships

The objective of the EFSD/JDRF/NN Research Fellowships is to support young investigators engaged in research focused on type 1 diabetes and its complications.

Postdoctoral Fellowships, each in the amount of Euro 50,000, will be awarded to individuals already holding a PhD, MD or equivalent degree. Application may be made by any paid-up member of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

The deadline date for this Programme is 1 July 2012.
Clinical Investigator Fellowships

The objective of the EFSD/Sanofi Clinical Investigator Fellowships is to encourage innovative clinical investigation and support talented young investigators engaged in diabetes research.

Postgraduate Fellowships, each in the amount of Euro 50,000, will be awarded to individuals already holding a basic medical qualification (MB, BS, MB ChB, MD, etc). Those holding higher degrees are also welcome to apply. All applicants must be paid-up members of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

The deadline date for this Programme is 15 March 2012.
Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2011 partnership programmes:

Bo Ahrén
Hadi Al Hasani
Angelo Avogaro
Francesco Beguinot
Christian Berne
Angelika Bierhaus
Nils Billestrup
Kåre Birkeland
Jonathan Bodansky
Riccardo Bonadonna
Ezio Bonifacio
Knut Borch-Johnsen
Miriam Cnop
Anne Cooke
Leszek Czupryniak
Hans De Vries
Helena Edlund
Decio L. Eizirik
Bo Feldt-Rasmussen
Paola Fioretto
Malin Flodström-Tullberg
Edwin Gale
Mauro Giacca
Peter Grant
Fiona Gribble
Per-Henrik Groop
Hans-Peter Hammes
Kristian Hanssen
Simon Heller
Norbert Hermanns
Khalida Ismail
Hannu Juvonen
Fredrik Karpe

David Klatzmann
Filip Knop
Anna Krook
Agnès Lehuen
Yannick Le Marchand-Brustel
Johnny Ludvigsson
Beat Lutz
Valeriya Lyssenko
Sten Madsbad
Pierre Maechler
Sally Marshall
Nikolaus Marx
Paolo Meda
Niels Møller
Eduard Montanya
Ulrich Müller
Jacques Philippe
Danny Pipeleers
Arne Östman
Andrew Renehan
Erik Renström
Guy Rutter
Coen Stehouwer
Jim Shaw
Giatgen Spinas
Norbert Stefan
Jean-François Tanti
Jeremy Tavare
Bernard Thorens
John Wilding
Yehiel Zick
Antonio Zorzano
EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:

President: U Smith - Göteborg
Vice President: F Bosch – Barcelona
Vice President: A Boulton - Manchester
Honorary Secretary: M Walker - Newcastle
Honorary Treasurer: G Spinas - Zürich
Editor in Chief - Diabetologia: J Zierath - Stockholm
Chairman PGEC: C Tack - Nijmegen

Chairman: P A Halban - Geneva

Scientific Board:
S Amiel – London
F Beguinit – Naples
F Bosch - Barcelona
A Boulton - Manchester
E Ferrannini - Pisa
T Pieber – Graz
G Soltész – Pecs
M Stumvoll – Leipzig
C Tack - Nijmegen

Executive Director: V Jörgens - Düsseldorf
Vice Director: M Grüsser - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0 Fax: + 49 211 75 84 69-29

www.EuropeanDiabetesFoundation.org
Email: Foundation@easd.org

Bank Details
Europäische Stiftung für Diabetesforschung – EFSD
Commerz Bank
Königsallee 37
40300 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00
SWIFT / BIC: DRES DE FF 300 IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number:15.2.1-St.767 and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547